These involve developing ICIs including monoclonal antibodies (mAbs) to block the immunosuppressive molecules and to improve the cytotoxicity of tumor-infiltrating lymphocytes such as CTLA4, PD1, and PD-L1. Here, PDCD1 is linked to neoplasm.